Melatonin Activates KEAP1/NRF2/PTGS2 Pathway to Attenuate Hyperoxia-Driven Ferroptosis in Bronchopulmonary Dysplasia
Journal of Inflammation Research · 2025-06 · Volume 18 · 7571-7583
DOI: 10.2147/jir.s520404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inflammation Research, 2025-06. Verfasst von Xianhui Deng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Jiangyin People's Hospital, Wuxi, People's Republic of China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background and Purposes: Ferroptosis, a type of regulated cell death, has been confirmed to play a role in the pathogenesis of bronchopulmonary dysplasia (BPD). This study aimed to test the hypothesis that melatonin mitigates hyperoxia-induced BPD by inhibiting ferroptosis in alveolar epithelial cells, specifically through modulation of the KEAP1/NRF2/PTGS2 signaling pathway.
Methods
Hyperoxia-induced MLE-12 cells and neonatal mice were used to establish BPD models. The effects of melatonin on hyperoxia-induced ferroptosis in MLE-12 cells were assessed by administering melatonin and ferroptosis inducer erastin to these cells. Key target genes involved in melatonin's ameliorative effects on BPD were identified using bioinformatics analysis. To confirm the regulatory relationship between melatonin and the KEAP1/NRF2/PTGS2 pathway, MLE-12 cells were treated with the NRF2 inhibitor ML385 under hyperoxic conditions. Additionally, molecular docking was performed to predict interactions between melatonin and KEAP1.
Results
Melatonin (MT) treatment up-regulated the expression of glutathione peroxidase 4 (GPX4) and xCT in hyperoxia-treated alveolar epithelial cells. The anti-ferroptosis effect of MT on these cells was significantly reduced by ML385, confirming the role of the KEAP1/NRF2 pathway in MT's mechanism of action. In vivo experiments demonstrated that MT up-regulated NRF2, GPX4, and xCT levels and down-regulated KEAP1 and PTGS2 levels in hyperoxia-induced BPD models.
Conclusion
Melatonin exerts a protective effect against hyperoxia-induced BPD by inhibiting ferroptosis in alveolar epithelial cells, and this effect is mediated, at least in part, through the KEAP1/NRF2/PTGS2 axis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neonatology, Jiangyin People's Hospital, Wuxi, People's Republic of China.
- Department of Neonatology, Affiliated Women's Hospital of Jiangnan University, Wuxi Maternity and Child Health Care Hospital, Wuxi, People's Republic of China.
ORCID-Profile: Renqiang Yu
Zitieren
APA
Deng, X., Xie, A., Ye, D., Ma, Y., Bao, Z., Xie, Q., Luo, Z., Wang, R., Li, H., & Yu, R. (2025). Melatonin Activates KEAP1/NRF2/PTGS2 Pathway to Attenuate Hyperoxia-Driven Ferroptosis in Bronchopulmonary Dysplasia. Journal of Inflammation Research, Volume 18, 7571-7583. https://doi.org/10.2147/jir.s520404
Vancouver
Deng X, Xie A, Ye D, Ma Y, Bao Z, Xie Q, et al. Melatonin Activates KEAP1/NRF2/PTGS2 Pathway to Attenuate Hyperoxia-Driven Ferroptosis in Bronchopulmonary Dysplasia. Journal of Inflammation Research. 2025;Volume 18:7571-7583. doi:10.2147/jir.s520404
BibTeX
@article{Deng2025,
author = {Deng, Xianhui and Xie, Anni and Ye, Danni and Ma, Yizhe and Bao, Zhidan and Xie, Qiuyan and Luo, Zichen and Wang, Ran and Li, Hu and Yu, Renqiang},
title = {Melatonin Activates KEAP1/NRF2/PTGS2 Pathway to Attenuate Hyperoxia-Driven Ferroptosis in Bronchopulmonary Dysplasia},
journal = {Journal of Inflammation Research},
year = {2025},
volume = {Volume 18},
pages = {7571--7583},
doi = {10.2147/jir.s520404}
}
EUVIMED